Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.62 |
| ▸ | JAK3 | P52333 | 18/20 | 0.62 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032879 | 0.91 | JAK2 (0.59) | JAK2JAK3 | |
| SCHEMBL15032876 | 0.86 | JAK2 (0.62) | JAK2JAK3 | |
| SCHEMBL4008367 | 0.83 | LIMK1 (0.51) | LIMK1LIMK2 | |
| SCHEMBL30595921 | 0.83 | LIMK1 (0.51) | LIMK1LIMK2 | |
| SCHEMBL30595935 | 0.83 | LIMK1 (0.59) | LIMK1LIMK2 | |
| SCHEMBL15032703 | 0.80 | JAK3 (0.61) | JAK2JAK3 | |
| SCHEMBL16245336 | 0.80 | JAK3 (0.61) | JAK2JAK3 | |
| SCHEMBL30595923 | 0.78 | LIMK1 (0.64) | LIMK1LIMK2 | |
| SCHEMBL15032885 | 0.77 | JAK2 (1.00) | JAK2JAK3 | |
| SCHEMBL30729891 | 0.76 | JAK1 (0.48) | LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | claimed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013085802-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK3 1/4885LIMK1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.